Appointments

Request an Appointment

Cancer Answer Line:
866.223.8100

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

Cancer Clinical Trials Results

IRBCCTitleHospitalStagePhaseDisease
BMTCTN 120214-419 Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT Main Campus  Blood & Marrow Transplant (BMT)
BMTCTN 120514-326 A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia and A Multi-Center, Phase III, Randomized Trial of Reduced Intensity Conditioning (RIC) and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow for Patients with Hematologic Malignancies Main Campus Phase 3Blood & Marrow Transplant (BMT), Hematologic Malignancy
CASE 1A1313-870 A Study of Low-dose Lenalidomide after Non-myeloablative Allogeneic Stem Main Campus  Blood & Marrow Transplant (BMT), Multiple Myeloma
CASE 2410CC1005 A Study of Hematopoietic Stem Cell Supermobilization in Patients with Non-Hodgkin Lymphoma Main Campus  Blood & Marrow Transplant (BMT), Lymphoma, Lymphoma, Non - Hodgkin
CBMT 1911CC00043 (Adult/Pediatric) KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor Main Campus  Blood & Marrow Transplant (BMT), Leukemia, Acute Myeloid (AML)
CBMT 1Z11CC00162 (Adult/Pediatric) A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications Main Campus  Blood & Marrow Transplant (BMT), Hematologic Malignancy
CTN 1101061208C A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients with Hematologic Malignancies Main Campus Phase 3Blood & Marrow Transplant (BMT), Hematologic Malignancy
FHCRC 200711-697 (Pediatric) Hematopoietic cell transplantation for treatment of patients with primary immunodeficiencies and other nonmalignant inherited disorders using low-dose TBI and fludarabine with or without Campath Main Campus  Blood & Marrow Transplant (BMT), Nonmalignant Inherited Disorders, Primary Immunodeficiencies
GNTM 1Z1212-840 (Pediatric) Defibrotide for patients with hepatic veno-occlusive disease (VOD): A treatment IND study (Under CFR 312.34) Main CampusStage 1 Blood & Marrow Transplant (BMT), Hepatic Veno-Occlusive Disease (VOD)

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).

Referrals

Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.

This information is provided by Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition.

© Copyright 2014 Cleveland Clinic. All rights reserved.